220513-49-5

Basic information

• Product Name: ISOBENZOFURAN, 5-BROMO-1,3-DIHYDRO-
• Synonyms: ISOBENZOFURAN, 5-BROMO-1,3-DIHYDRO-;5-Bromo-1,3-dihydro-isobenzofuran;5-bromo-1,3-dihydro-2-benzofuran
• CAS NO: 220513-49-5
• Molecular Formula: C8H7BrO
• Molecular Weight: 199.04
• Mol File: 220513-49-5.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 257.183°C at 760 mmHg
• Flash Point: 101.866°C
• Appearance: /
• Density: 1.583g/cm³
• Vapor Pressure: 0.024mmHg at 25°C
• Refractive Index: 1.602
• CAS DataBase Reference: ISOBENZOFURAN, 5-BROMO-1,3-DIHYDRO-(CAS DataBase Reference)
• NIST Chemistry Reference: ISOBENZOFURAN, 5-BROMO-1,3-DIHYDRO-(220513-49-5)
• EPA Substance Registry System: ISOBENZOFURAN, 5-BROMO-1,3-DIHYDRO-(220513-49-5)

Safety Data

• Hazardous Substances Data: 220513-49-5(Hazardous Substances Data)

Usage

General Description

5-Bromo-1,3-dihydro-isobenzofuran is a chemical compound with the formula C8H7BrO. It is a colorless to pale yellow liquid that is primarily used as an intermediate for the synthesis of pharmaceuticals and agrochemicals. ISOBENZOFURAN, 5-BROMO-1,3-DIHYDRO- has potential applications in medicinal chemistry due to its ability to act as a building block for various drugs and bioactive molecules. It can also be used in the production of perfumes and flavors. The 5-bromo-1,3-dihydro-isobenzofuran is known for its strong reactive property which makes it a valuable compound in organic synthesis. However, it should be handled and stored with care due to its potential hazards if not properly managed.

InChI:InChI=1/C8H7BrO/c9-8-2-1-6-4-10-5-7(6)3-8/h1-3H,4-5H2

Upstream product

• 61964-08-7 1,3-dihydro-isobenzofuran-5-ylamine 
• 86-90-8 4-bromophthalic anhydride 
• 171011-37-3 4-bromo-2-(hydroxymethyl)benzyl alcohol 
• 64169-34-2 5-bromophthalide 
• 13209-32-0 4-bromophthalaldehyde 

Downstream Products

• 89424-83-9 1,3-dihydroisobenzofuran-5-carbaldehyde 
• 64169-34-2 5-bromophthalide 

Relevant articles and documents

Optimization of Orally Bioavailable PI3KδInhibitors and Identification of Vps34 as a Key Selectivity Target

Optimization of a lead series of PI3Kδinhibitors based on a dihydroisobenzofuran core led to the identification of potent, orally bioavailable compound 19. Selectivity profiling of compound 19 showed similar potency for class III PI3K, Vps34, and PI3Kδ, and compound 19 was not well-tolerated in a 7-day rat toxicity study. Structure-based design led to an improvement in selectivity for PI3Kδover Vps34 and, a focus on oral phramacokinetics properties resulted in the discovery of compound 41, which showed improved toxicological outcomes at similar exposure levels to compound 19.

COMPOUNDS AND COMPOSITIONS AND USES THEREOF

Disclosed are compounds of formula (I): and pharmaceutical compositions containing such compounds. Methods of treating neurological or psychiatric disease and disorders in a subject in need are also disclosed.

PYRAZOLE COMPOUNDS AND METHODS OF MAKING AND USING SAME

Provided herein are pyrazole compounds and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL and/or ABHD6. Furthermore, the subject compounds and compositions are useful for the treatment of, for example, pain.